JP2010523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523676A5
JP2010523676A5 JP2010503070A JP2010503070A JP2010523676A5 JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5 JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5
Authority
JP
Japan
Prior art keywords
composition
liposome
peptide
hiv
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523676A (ja
Filing date
Publication date
Priority claimed from US11/785,077 external-priority patent/US9402893B2/en
Priority claimed from US11/812,992 external-priority patent/US20080057075A1/en
Application filed filed Critical
Priority claimed from PCT/US2008/004709 external-priority patent/WO2008127651A1/en
Publication of JP2010523676A publication Critical patent/JP2010523676A/ja
Publication of JP2010523676A5 publication Critical patent/JP2010523676A5/ja
Pending legal-status Critical Current

Links

JP2010503070A 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法 Pending JP2010523676A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/785,077 US9402893B2 (en) 2005-04-12 2007-04-13 Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
US11/812,992 US20080057075A1 (en) 2005-04-12 2007-06-22 Method of inducing neutralizing antibodies to human immunodeficiency virus
US96041307P 2007-09-28 2007-09-28
PCT/US2008/004709 WO2008127651A1 (en) 2007-04-13 2008-04-11 Method of inducing neutralizing antibodies to human immunodeficiency virus

Publications (2)

Publication Number Publication Date
JP2010523676A JP2010523676A (ja) 2010-07-15
JP2010523676A5 true JP2010523676A5 (https=) 2010-11-18

Family

ID=39864256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503070A Pending JP2010523676A (ja) 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法

Country Status (6)

Country Link
US (2) US8956627B2 (https=)
EP (1) EP2139516A4 (https=)
JP (1) JP2010523676A (https=)
AU (1) AU2008239628B2 (https=)
CA (1) CA2683752A1 (https=)
WO (1) WO2008127651A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2139516A4 (en) 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2331104A4 (en) * 2008-09-05 2012-10-17 Univ Duke METHOD FOR INDUCING AN ANTIVIRAL IMMUNE RESPONSE
CA2757240A1 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
WO2011106100A2 (en) 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies
EP2822599A4 (en) * 2012-03-05 2015-12-23 Univ Duke VACCINE FORMULATION
US10076567B2 (en) * 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US4994440A (en) 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
DE570357T1 (de) 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
WO1994020141A1 (en) 1993-03-11 1994-09-15 The University Of Southern California Therapeutic strategies for immunoinfective cluster virus infections
ES2204919T3 (es) 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
JPH09501169A (ja) * 1993-08-06 1997-02-04 オパーバス ホールディング ビー ヴィ 小胞に生体高分子物質を高度に充填する方法
DE69426725T2 (de) 1993-09-11 2001-09-06 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
JPH10504798A (ja) 1994-03-14 1998-05-12 ユニバーシティー オブ サウザーン カリフォルニア Ｈｉｖ−１感染の診断方法および処置方法
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
MX9708008A (es) * 1995-04-19 1998-03-31 Polymun Scient Immunbio Forsch Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.
AU5978596A (en) * 1995-06-07 1996-12-30 U.S. Department Of The Army Liposomes containing human immunodeficiency virus glycoprote in and methods for use thereof
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5901306A (en) * 1997-06-23 1999-05-04 Sun Microsystems, Inc. Method and apparatus for reducing a computational result to the range boundaries of a signed 8-bit integer in case of overflow
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
US7595049B2 (en) 2001-09-07 2009-09-29 Polymun Scientific Immunobiologische Forschung Gmbh IGG1 monoclonal antibody with anti-HIV neutralizing activity
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
ATE444310T1 (de) 2002-01-17 2009-10-15 Polymun Scient Immunbio Forsch Antiidiotypische antikörper die hiv-1 neutralisierende antikörper induzieren
US7790159B2 (en) 2002-07-15 2010-09-07 Board Of Regents, The University Of Texas System Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids
US7906115B2 (en) 2002-07-15 2011-03-15 Thorpe Philip E Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US20040131622A1 (en) 2002-07-15 2004-07-08 Board Of Regents Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids
US7611704B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
EP2357009A1 (en) 2002-07-15 2011-08-17 Board of Regents, The University of Texas System Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
EP1613643A4 (en) 2003-03-27 2009-10-28 Sudhir Paul LUPUS ANTIBODIES FOR THE PASSIVE IMMUNE THERAPY OF HIV / AIDS
WO2005111079A2 (en) 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
US20080057075A1 (en) 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2139516A4 (en) 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
BRPI0811228A2 (pt) 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
US20120070488A1 (en) 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
AU2010232916A1 (en) 2009-04-03 2011-10-27 Children's Medical Center Corporation Formulation
CA2757240A1 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Similar Documents

Publication Publication Date Title
JP2010523676A5 (https=)
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
US5352576A (en) Method of determining the presence and titers of anti HIV-1 ag27bodies
JP2018502885A5 (https=)
Pitisuttithum et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
DE60329106D1 (de) Ghrelin-träger-konjugate
JP2013181034A5 (https=)
JP2007505033A5 (https=)
PE20071055A1 (es) Anticuerpos anti mn
CN1505528A (zh) 包含结合hiv包膜蛋白的配体的免疫原
JP2013505201A5 (https=)
NZ597458A (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
King et al. Achieving cross-reactivity with pan-ebolavirus antibodies
JP2013523783A5 (https=)
JP2010523676A (ja) ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
Sjölander et al. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-ISCOM preparations. A comparison with other adjuvant systems
NZ515356A (en) Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
MX2011007745A (es) Division de gp41.
ATE343592T1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
Xiao et al. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus‐1 envelope protein
Iglesias et al. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg
Kelker et al. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein